Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Irinotecan
Accession Number
DB00762  (APRD00579)
Type
Small Molecule
Groups
Approved, Investigational
Description

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Structure
Thumb
Synonyms
  • (+)-Irinotecan
  • Irinotecan
  • Irinotecan lactone
  • Irinotecanum
Product Ingredients
IngredientUNIICASInChI Key
Irinotecan hydrochloride06X131E4OE100286-90-6GURKHSYORGJETM-WAQYZQTGSA-N
Irinotecan hydrochloride hydrate042LAQ1IIS136572-09-3KLEAIHJJLUAXIQ-JDRGBKBRSA-N
Irinotecan sucrosofateOL741S3N8B1361317-83-0BCPSLKYBXGKPIW-RTXWKGGWSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CamptosarInjection, solution20 mg/1mLIntravenousPharmacia and Upjohn Company LLC1996-06-14Not applicableUs
CamptosarSolution20 mgIntravenousPfizer Canada Ulc1997-08-27Not applicableCanada
CamptosarInjection, solution20 mg/1mLIntravenousPharmacia & Upjohn Inc1996-06-14Not applicableUs
IrinotecanSolutionIntravenousPfizer Canada Ulc2014-03-07Not applicableCanada
Irinotecan for InjectionSolutionIntravenousTEVA Canada Limited2008-10-31Not applicableCanada
Irinotecan HydrochlorideInjection20 mg/1mLIntravenousSagent Pharmaceuticals, Inc. (USA)2008-11-282008-12-11Us
Irinotecan Hydrochloride InjectionSolutionIntravenousTeligent Ou2015-05-28Not applicableCanada
Irinotecan Hydrochloride Injection USPSolutionIntravenousAccord Healthcare Inc2013-05-06Not applicableCanada
Irinotecan Hydrochloride Injection USPSolutionIntravenousPfizer Canada Ulc2006-02-01Not applicableCanada
Irinotecan Hydrochloride Injection, USPSolutionIntravenousQilu Pharmaceutical Co. LtdNot applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Irinotecan HydrochlorideInjection, solution20 mg/1mLIntravenousSandoz2008-02-272009-12-18Us
Irinotecan HydrochlorideInjection, solution40 mg/2mLIntravenousTeva Parenteral Medicines, Inc.2008-02-282019-11-30Us
Irinotecan HydrochlorideInjection20 mg/1mLIntravenousWest-Ward Pharmaceuticals Corp2010-12-20Not applicableUs
Irinotecan HydrochlorideInjection20 mg/1mLIntravenousHeritage2012-06-20Not applicableUs
Irinotecan HydrochlorideInjection20 mg/1mLIntravenousNorth Star Rx Llc2017-06-15Not applicableUs
Irinotecan HydrochlorideInjection, solution20 mg/1mLIntravenousSagent Pharmaceuticals2014-08-15Not applicableUs
Irinotecan HydrochlorideInjection40 mg/2mLIntravenousJiangsu Hengrui Pharmaceutical Co., Ltd.2011-12-162013-03-08Us
Irinotecan HydrochlorideInjection, solution20 mg/1mLIntravenousQilu Pharmaceutical Co., Ltd.2016-05-03Not applicableUs
Irinotecan HydrochlorideInjection20 mg/1mLIntravenousAreva Pharmaceuticals,Inc.2008-02-20Not applicableUs
Irinotecan HydrochlorideInjection20 mg/1mLIntravenousWest-Ward Pharmaceuticals Corp2010-12-20Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
International/Other Brands
Biotecan / Campto (YakultHonsha Co. Ltd.)
Categories
UNII
7673326042
CAS number
97682-44-5
Weight
Average: 586.678
Monoisotopic: 586.279134968
Chemical Formula
C33H38N4O6
InChI Key
UWKQSNNFCGGAFS-XIFFEERXSA-N
InChI
InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
IUPAC Name
(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate
SMILES
CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12

Pharmacology

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Pharmacodynamics

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a semisynthetic derivative of camptothecin. Camptothecins interact specifically with topoisomerase I, an enzyme in the cell nucleus that regulates DNA topology and facilitates nuclear processes such as DNA replication, recombination, and repair. During these processes, topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks, allowing single DNA strands to pass through the break. The 3'-DNA terminus of the broken DNA strands bind covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After the DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the chemically unaltered topoisomers that allow transcription to proceed. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

Mechanism of action

Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.

TargetActionsOrganism
ADNA topoisomerase 1
inhibitor
Humans
ADNA topoisomerase I, mitochondrial
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

The maximum plasma concentration (Cmax) when a dose of 125 mg/m^2 is given to patients with solid tumours is 1660 ng/mL. The AUC (0-24) is 10,200 ng·h/mL. The Cmax when a dose of 340 mg/m^2 is given to patients with solid tumours is 3392 ng/mL. The AUC (0-24) is 20,604 ng·h/mL.

Volume of distribution

The volume of distribution of terminal elimination phase is 110 L/m^2 when a dose of 125 mg/m^2 is given to patients with solid tumours. The volume of distribution of terminal elimination phase is 234 L/m^2 when a dose of 340 mg/m^2 is given to patients with solid tumours.

Protein binding

30%-68% protein bound, mainly to albumin.

Metabolism

Hepatic. The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite.

Route of elimination

The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m2) to 50% (300 mg/m2).

Half life

The half life of irinotecan is about 6 - 12 hours. The terminal elimination half-life of the active metabolite, SN-38 is 10 - 20 hours.

Clearance
  • 13.3 L/h/m^2 [Dose of 125 mg/m^2, patients with solid tumours]
  • 13.9 L/h/m^2 [Dose of 340 mg/m^2, patients with solid tumours]
Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Irinotecan Metabolism PathwayDrug metabolism
Irinotecan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Solute carrier organic anion transporter family member 1B1SLCO1B1*15(C;C) / (C;T)C Allele / G AlleleDirectly Studied EffectPatients with this genotype have reduced transport of the active metabolite of irinotecan resulting in increased plasma concentrations.Details
UDP-glucuronosyltransferase 1-1UGT1A1*28 or UGT1A 7/7Not Availableextra TA in promoterADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.Details
UDP-glucuronosyltransferase 1-7UGT1A7*2/*2(A;A) / (A;C) / (A;G) / (G;G) / (G;T)G allele / A allele  … show all ADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.Details
UDP-glucuronosyltransferase 1-1UGT1A1*93(A;A) / (A;G)A AlleleADR Directly StudiedThe presence of this genotype in UGT1A1 may indicate an increased risk of bone marrow toxicity when treated with irinotecan.Details
UDP-glucuronosyltransferase 1-1UGT1A1*28Not Availableextra TA in promoter, homozygousADR Directly StudiedPatients who carry this genotype in UGT1A1 are at increased risk for neutropenia following initiation of irinotecan treatment.Details

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Irinotecan.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Irinotecan.
1,10-Phenanthroline1,10-Phenanthroline may increase the neuromuscular blocking activities of Irinotecan.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Irinotecan is combined with 2-Methoxyethanol.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Irinotecan.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Irinotecan.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Irinotecan.
6-Deoxyerythronolide BThe metabolism of Irinotecan can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Irinotecan.
7-ethyl-10-hydroxycamptothecinThe metabolism of Irinotecan can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

Synthesis Reference
US4604463
General References
  1. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8. [PubMed:15007088]
  2. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006 Oct 1;24(28):4534-8. [PubMed:17008691]
  3. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  4. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
External Links
Human Metabolome Database
HMDB0014900
KEGG Drug
D08086
KEGG Compound
C16641
PubChem Compound
60838
PubChem Substance
46505871
ChemSpider
54825
BindingDB
50128267
ChEBI
80630
ChEMBL
CHEMBL481
Therapeutic Targets Database
DAP001339
PharmGKB
PA450085
HET
CP0
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Irinotecan
ATC Codes
L01XX19 — Irinotecan
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1u65
FDA label
Download (132 KB)
MSDS
Download (36.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Sarcomas1
0CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
0CompletedTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / Newly Diagnosed High-Grade Gliomas1
0CompletedTreatmentResectable Pancreatic Cancers1
0Not Yet RecruitingTreatmentChildhood CNS Tumor1
0RecruitingTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
0RecruitingTreatmentBorderline Pancreatic Inoperable Cancer / Locally Advanced Pancreatic Cancer / Malignant Neoplasm of Pancreas1
0RecruitingTreatmentNeuroblastoma (NB)1
0TerminatedTreatmentGlioblastomas / Gliosarcoma / Neoplasms, Brain1
1Active Not RecruitingBasic ScienceAdvanced Colorectal Cancer1
1Active Not RecruitingOtherPediatric Oncology1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Adenocarcinoma of the Gallbladder / Adenocarcinoma of Unknown Primary / Adult Primary Cholangiocellular Carcinoma / Advanced Adult Primary Liver Cancer / Advanced Gastric Cancer / Cholangiocarcinoma of the Extrahepatic Bile Duct / Cholangiocarcinoma of the Gallbladder / Diffuse Adenocarcinoma of the Stomach / Duct Cell Adenocarcinoma of the Pancreas / Intestinal Adenocarcinoma of the Stomach / Localized Unresectable Adult Primary Liver Cancer / Metastatic Carcinoma of Unknown Primary / Metastatic Extrahepatic Bile Duct Cancer / Mixed Adenocarcinoma of the Stomach / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Newly Diagnosed Carcinoma of Unknown Primary / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Gastric Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Gallbladder Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Gallbladder Cancer / Stage IVB Rectal Cancer / Unresectable Extrahepatic Bile Duct Cancer1
1Active Not RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
1Active Not RecruitingTreatmentAdult Hodgkin Lymphoma / Adult Non-Hodgkin's Lymphoma / Advanced Malignant Solid Neoplasm / Carcinoma, Breast / Carcinoma, Pancreatic / Colon Carcinoma / Deleterious BRCA1 Gene Mutation / Estrogen Receptor Negative / HER2/Neu Negative / Lung, Carcinoma / Lymphoma, Hodgkins / Metastatic Colon Cancer / Metastatic Malignant Neoplasm / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Neoplasms, Advanced Solid / Non-Hodgkin's Lymphoma (NHL) / Ovarian Carcinoma / Progesterone Receptor Negative / Solid Neoplasms / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage III Colon Cancer / Stage III Colon Cancer AJCC v7 / Stage III Lung Cancer / Stage III Lung Cancer AJCC v7 / Stage III Ovarian Cancer / Stage III Ovarian Cancer AJCC v6 and v7 / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIA Colon Cancer / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIB Colon Cancer / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IIIC Colon Cancer / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Lung Cancer / Stage IV Lung Cancer AJCC v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Colon Cancer / Stage IVA Colon Cancer AJCC v7 / Stage IVA Pancreatic Cancer / Stage IVB Colon Cancer / Stage IVB Colon Cancer AJCC v7 / Stage IVB Pancreatic Cancer / Triple-Negative Breast Carcinoma / Unresectable Malignant Neoplasm / Unresectable Solid Neoplasm1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Cancers / BRAF NP_004324.2:p.V600X / KRAS wt Allele / Metastatic Malignant Solid Neoplasm / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v7 / Unresectable Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Solid Tumors1
1Active Not RecruitingTreatmentAdvanced Solid Tumours1
1Active Not RecruitingTreatmentCancer, Advanced / Malignant Solid Tumours / Metastatic Cancers1
1Active Not RecruitingTreatmentChildhood Solid Tumors1
1Active Not RecruitingTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas3
1Active Not RecruitingTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor1
1Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1Active Not RecruitingTreatmentPrimary Brain Tumors / Tumors, Solid1
1Active Not RecruitingTreatmentRefractory Solid Tumors / Relapsed Solid Tumors1
1CompletedDiagnosticMalignancies / Refractory Solid Tumors1
1CompletedDiagnosticMalignant Lymphomas / Tumors1
1CompletedOtherER/PR Positive Breast Cancer / Metastatic Breast Cancer With Active Brain Metastasis / Triple Negative Breast Cancer (TNBC) / Tumors, Solid1
1CompletedTreatmentAIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAdenocarcinoma of the Pancreas1
1CompletedTreatmentAdenocarcinomas / Colorectal / Metastatic1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Stomach1
1CompletedTreatmentAdvanced Adult Primary Liver Cancer / Advanced Gastric Cancer / Carcinoma of the Appendix / Estrogen Receptor-negative Breast Cancer / Extensive Stage Small Cell Lung Cancer / Gastrointestinal Stromal Tumors / HER2-Negative Breast Cancer / Metastatic Colon Cancer / Metastatic Gastrointestinal Carcinoid Tumor / Non-Small Cell Lung Cancer Recurrent / Ovarian Sarcoma / Ovarian Stromal Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Adult Primary Liver Cancer / Recurrent Anal Cancer / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor / Recurrent Breast Cancer / Recurrent Cervical Cancer / Recurrent Colon Cancer / Recurrent Endometrial Carcinoma / Recurrent Esophageal Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Recurrent Gastric Cancer / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Pancreatic Cancer / Recurrent Prostate Cancer / Recurrent Rectal Cancer / Recurrent Salivary Gland Cancer / Recurrent Small Intestine Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Refractory Small cell lung cancer / Small Intestine Adenocarcinoma / Small Intestine Leiomyosarcoma / Small Intestine Lymphoma / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Anal Cancer / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor / Stage IV Breast Cancer / Stage IV Endometrial Carcinoma / Stage IV Esophageal Cancer / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Pancreatic Cancer / Stage IV Prostate Cancer / Stage IV Rectal Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer / Triple-Negative Breast Cancer (TNBC) / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentAdvanced Gastrointestinal Tumors1
1CompletedTreatmentAdvanced Nonhematologic Malignancies1
1CompletedTreatmentAdvanced Solid Malignancies2
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors / Colorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Head and Neck Cancer / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentAdvanced Solid Tumors / Hepatocellular,Carcinoma1
1CompletedTreatmentAnal Carcinoma / Carcinoid tumour of the gastrointestinal tract / Carcinoma of the Appendix / Colorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Gastrointestinal Stromal Tumors / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Intestine Cancer1
1CompletedTreatmentAnal Carcinoma / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Esophageal Cancers / Extrahepatic Bile Duct Cancer / Gallbladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Small Intestine Cancer1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Glioblastomas / Gliosarcoma1
1CompletedTreatmentAstrocytoma, Oligoastrocytoma, Mixed / Ganglioglioma / Ganglioneuroma / Glioblastoma Multiforme Glioma / Gliomas1
1CompletedTreatmentBile Duct Carcinoma / Duodenum Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Renal Cancers1
1CompletedTreatmentBrain and Central Nervous System Tumors4
1CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
1CompletedTreatmentBrain and Central Nervous System Tumors / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentBrain and Nervous System / Malignancies1
1CompletedTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic / Pancreas Neoplasms1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancer, Advanced / Liver Cancer1
1CompletedTreatmentCancer, Advanced / Tumors, Solid1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Tumors1
1CompletedTreatmentCarcinoma, Colorectal1
1CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1CompletedTreatmentCervix Cancer1
1CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway Glioma / Recurrent Colon Cancer / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Melanoma / Recurrent Nasopharyngeal Cancer / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers8
1CompletedTreatmentColorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Other Tumors With EGFR Dependence / Squamous Cell Head and Neck Cancer / Triple Negative Breast Cancer (TNBC)1
1CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
1CompletedTreatmentColorectal Cancers / Severe or persistent diarrhea1
1CompletedTreatmentDigestive Cancers1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Neutropenias / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Neuroblastomas / Severe or persistent diarrhea1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentEsophageal Cancers / Liver Cancer / Malignant Neoplasm of Stomach1
1CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
1CompletedTreatmentEwing's Sarcoma Family of Tumors / Neoplasms, Brain / Neuroblastomas / Rhabdomyosarcoma and Other Soft Tissue Sarcomas / Sarcoma, Osteogenic1
1CompletedTreatmentGastro-Intestinal Cancer1
1CompletedTreatmentGlioblastomas2
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentGlioblastomas / Neuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic1
1CompletedTreatmentKRAS Mutant Metastatic Colorectal Cancer1
1CompletedTreatmentLeukemias1
1CompletedTreatmentCancer treatment / Liver Dysfunction / Neoplasms, Solid Tumor / Unspecified Adult Solid Tumor1
1CompletedTreatmentLung Cancers7
1CompletedTreatmentMalignancies5
1CompletedTreatmentMalignancies / Tumors, Solid1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMetastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Rectal Cancer1
1CompletedTreatmentMetastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Rectal Cancer1
1CompletedTreatmentMetastatic Colorectal Cancer (MCRC) / Metastatic Colorectal Cancers1
1CompletedTreatmentMetastatic Colorectal Cancers4
1CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms Metastasis1
1CompletedTreatmentNeoplasms, Gastrointestinal1
1CompletedTreatmentNeoplasms, Pancreatic2
1CompletedTreatmentNeoplasms / Severe or persistent diarrhea1
1CompletedTreatmentNeuroblastomas3
1CompletedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1CompletedTreatmentRefractory Solid Tumors in Children1
1CompletedTreatmentSquamous Cell Carcinoma of Esophagus1
1CompletedTreatmentStomach Neoplasms1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Central Nervous System1
1CompletedTreatmentTumors, Solid6
1CompletedTreatmentUnresectable Advanced Cancer1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific29
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific6
1Enrolling by InvitationOtherMetastatic Colorectal Cancers1
1Enrolling by InvitationTreatmentHigh Grade Glioma (HGG)1
1Not Yet RecruitingTreatmentEwing's Sarcoma (ES)1
1Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentAdenocarcinoma of the Pancreas1
1RecruitingTreatmentAdenocarcinoma, Mucinous / Colorectal Cancers / Malignant Neoplasm of Stomach / Malignant Peritoneal Neoplasm / Mesothelioma / Mucinous Tumor / Primary Peritoneal Carcinoma / Pseudomyxoma Peritonei1
1RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligoastrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Gliomas / Progressive Disease / Recurrent Adult Brain Tumor / Recurrent Anaplastic Astrocytoma / Recurrent Anaplastic Oligoastrocytoma / Recurrent Anaplastic Oligodendroglioma / Recurrent Glioblastoma / Recurrent Gliosarcoma / Recurrent Malignant Gliomas / Recurrent WHO Grade III Glioma / UGT1A1*28 Allele Negative1
1RecruitingTreatmentAdult Solid Neoplasm / Advanced Malignant Solid Neoplasm / Metastatic Malignant Neoplasm / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Neoplasms, Advanced Solid / Refractory Malignant Neoplasm / Unresectable Malignant Neoplasm / Unresectable Solid Neoplasm1
1RecruitingTreatmentAdvanced Cancers / Advanced Malignant Neoplasm / Recurrent Malignant Neoplasm / Refractory Malignant Neoplasm1
1RecruitingTreatmentAdvanced Solid Tumors2
1RecruitingTreatmentBladder Cancers / Cancer of the Ovary / Cholangiocarcinomas / Malignant Neoplasm of Colon / Malignant Neoplasm of Stomach / Palpable Subcutaneous Malignant Lesions / Tumors, Solid1
1RecruitingTreatmentCachexia / Malignant Neoplasm of Pancreas / Obese experiencing rapid weight loss1
1RecruitingTreatmentCancer of the Pancreas / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentCancer, Advanced / Neoplasms1
1RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1RecruitingTreatmentChildhood Solid Neoplasm / Recurrent Central Nervous System Neoplasm / Recurrent Malignant Solid Neoplasm / Recurrent Solid Neoplasm / Refractory Central Nervous System Neoplasm / Refractory Malignant Solid Neoplasm1
1RecruitingTreatmentColorectal Cancers / Gastrooesophageal Cancer / Renal Cell Adenocarcinoma1
1RecruitingTreatmentColorectal Cancers / Malignant Neoplasms of Digestive Organs / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / Ewing's Sarcoma (ES) / Medulloblastomas / Neuroblastomas / Rhabdoid Tumors / Rhabdomyosarcomas / Tumors, Solid1
1RecruitingTreatmentEwing's Sarcoma (ES)2
1RecruitingTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Recurrent or Refractory Solid Tumors / Rhabdomyosarcomas / Sarcoma, Osteogenic1
1RecruitingTreatmentGastric Adenocarcinoma / Gastrooesophageal Cancer1
1RecruitingTreatmentGastrooesophageal Cancer1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentMetastatic Colorectal Cancers3
1RecruitingTreatmentRecurrent Central Nervous System Neoplasm / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm / Refractory Lymphomas / Refractory Malignant Solid Neoplasm1
1RecruitingTreatmentRefractory Solid Tumors1
1RecruitingTreatmentSarcomas1
1RecruitingTreatmentSolid Tumor Cancers1
1RecruitingTreatmentSolid Tumor, Unspecified, Adult1
1RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
1RecruitingTreatmentTumors, Solid2
1SuspendedTreatmentAdvanced Gastric Cancer / Estrogen Receptor Negative / HER2/Neu Negative / Malignant Solid Neoplasm / Neuroendocrine Neoplasms / Progesterone Receptor Negative / Recurrent, IV-B Cervical cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Gastric Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Small Cell Lung Carcinoma / Triple-Negative Breast Carcinoma1
1TerminatedBasic ScienceCancer, Advanced1
1TerminatedTreatmentAdvanced Solid Malignancies / Advanced Solid Tumors / Malignancies1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentColorectal Cancers1
1TerminatedTreatmentColorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentEsophageal Cancers1
1TerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach2
1TerminatedTreatmentHepatic Metastases / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1TerminatedTreatmentMalignant Gliomas1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1TerminatedTreatmentMelanoma / Neoplasm Metastases / Neoplasms, Colorectal1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentPancreatic Ductal Adenocarcinoma (PDAC)1
1TerminatedTreatmentSarcomas1
1TerminatedTreatmentTumors, Solid1
1Unknown StatusTreatmentColorectal Cancers1
1Unknown StatusTreatmentLeukemia, Acute1
1Unknown StatusTreatmentNeoplasm, Gastric / Neoplasms, Colorectal / Secondary1
1Unknown StatusTreatmentRectal Carcinoma1
1Unknown StatusTreatmentRefractory Solid Tumors in Children1
1Unknown StatusTreatmentTumors, Solid1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnBasic ScienceAdvanced Adenocarcinoma of the Colon or Rectum1
1WithdrawnTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1WithdrawnTreatmentStage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1, 2Active Not RecruitingTreatmentAdvanced Gastrointestinal Cancers1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic2
1, 2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma of Unknown Primary / Adult Cholangiocarcinoma / Advanced Gastric Cancer / Carcinoma of Gallbladder / Gastric Adenocarcinoma / Malignant Gastrointestinal Neoplasm / Pancreatic Adenocarcinoma Metastatic / Stage III Ampulla of Vater Cancer / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IV Ampulla of Vater Cancer / Stage IV Gallbladder Cancer / Stage IV Pancreatic Cancer1
1, 2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Metastatic Colon Cancer / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Rectal Cancer2
1, 2CompletedTreatmentAdvanced Gastric Cancer1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors3
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Adults / Long-Term Effects Secondary to Cancer Therapy in Children / Poor Performance Status / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentCarcinoma, Colorectal / CRC1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Tumors / Neoplasms, Colorectal1
1, 2CompletedTreatmentChemonaive / Extensive Stage Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentColorectal Cancers8
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentMalignant Gliomas1
1, 2CompletedTreatmentMalignant Neoplasm of Stomach1
1, 2CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
1, 2CompletedTreatmentMetastatic Colorectal Cancers3
1, 2CompletedTreatmentNeuroblastomas1
1, 2CompletedTreatmentPediatric Solid Tumors1
1, 2CompletedTreatmentRectal Carcinoma1
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Not Yet RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Locally Advanced Unresectable Gastric Adenocarcinoma / Metastatic Gastroesophageal Junction Adenocarcinoma / Metastatic Unresectable Gastric Adenocarcinoma / Unresectable Gastroesophageal Junction Adenocarcinoma1
1, 2Not Yet RecruitingTreatmentCancer of Colon / Cancer of Liver / Cancer of Pancreas / Cancer of Rectum / Cancer, Gall Bladder / Glioblastoma Multiforme (GBM) / Myeloma Multiple1
1, 2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers / Tumors, Solid1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas / Bladder Cancers / Bone Cancer / Bone Metastases / Bone Neoplasms / Cancer of the Ovary / Cancer, Breast / Glioblastoma Multiforme (GBM) / Malignancies / Malignancies Multiple / Malignant Gliomas / Malignant Lymphomas / Malignant Neoplasm of Pancreas / Neoplasm of Bone / Neoplasm of Lung / Neoplasms Metastasis / Neoplasms Pancreatic / Neoplasms, Breast / Neoplasms, Colorectal / Neoplasms, Pancreatic / Refractory Brain Tumor / Refractory Cancer / Refractory Neoplasm / Refractory Non-Hodgkin's lymphoma / Renal Cancers / Resistant Cancer / Sarcomas1
1, 2RecruitingTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
1, 2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Biliary System Disorder / BRCA1 Gene Mutation / Brca2 Gene Mutation / Homologous Recombination Deficiency / PALB2 Gene Mutation / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer AJCC v7 / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
1, 2RecruitingTreatmentAdenocarcinomas / Digestive System Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Endocrine System Diseases / Neoplasm, Glandular / Neoplasms / Neoplasms Pancreatic / Neoplasms, Pancreatic / Pancreatic Diseases1
1, 2RecruitingTreatmentAdvanced Gastric Cancer / Colorectal Adenocarcinoma / Gastric Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer / Unresectable Pancreatic Carcinoma1
1, 2RecruitingTreatmentAdvanced Solid Tumors1
1, 2RecruitingTreatmentAnaplastic Astrocytoma (AA) / Brain Stem Gliomas / Diffuse Intrinsic Pontine Glioma (DIPG) / DIPG / Glioblastoma Multiforme (GBM) / Glioma, Astrocytic / Gliosarcoma / Low-Grade Gliomas / Optic Nerve Glioma / Pilocytic Astrocytoma / Pilomyxoid Astrocytoma / Pleomorphic Xanthoastrocytoma1
1, 2RecruitingTreatmentBiliary Tract Cancer1
1, 2RecruitingTreatmentBorderline Resectable Pancreatic Adenocarcinoma / Resectable Pancreatic Ductal Adenocarcinoma1
1, 2RecruitingTreatmentCentral Nervous System Embryonal Tumor With Rhabdoid Features / Central Nervous System Embryonal Tumor, Not Otherwise Specified / Central Nervous System Ganglioneuroblastoma / Childhood Central Nervous System Neoplasm / Childhood Solid Neoplasm / Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Pinealoblastoma / Primary Central Nervous System Neoplasm / Recurrent Childhood Central Nervous System Embryonal Neoplasm / Recurrent Childhood Medulloblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Malignant Solid Neoplasm / Recurrent Medulloblastoma / Recurrent Neuroblastoma / Recurrent Rhabdomyosarcoma / Recurrent Solid Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Medulloblastoma / Refractory Neuroblastoma / Refractory Rhabdomyosarcoma1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentColo-rectal Cancer1
1, 2RecruitingTreatmentColorectal Cancers / Malignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentColorectal Cancers / Metastatic Colorectal Cancers / RAS Wild Type Colorectal Cancer / Refractory Colorectal Cancer1
1, 2RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Rhabdomyosarcomas1
1, 2RecruitingTreatmentEwing's Sarcoma (ES) / Non-rhabdomyosarcoma Soft Tissue Sarcomas / Refractory or Recurrent Solid Tumors / Rhabdomyosarcomas1
1, 2RecruitingTreatmentEwing's Tumor Metastatic1
1, 2RecruitingTreatmentGBM / Glioblastoma Multiforme (GBM) / Glioblastomas1
1, 2RecruitingTreatmentHigh-Grade Gliomas1
1, 2RecruitingTreatmentIrinotecan Sensitive Cancers / Non Small Cell Lung Carcinoma (NSCLC) / Small Cell Lung Carcinoma1
1, 2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentNeoplasms, Colorectal1
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
1, 2TerminatedTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2TerminatedTreatmentCancer, Advanced / Carcinoma, Colorectal / Endometrial / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Renal Cell Adenocarcinoma / Uterine1
1, 2TerminatedTreatmentCarcinoma, Colorectal1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentExtensive Stage Unresectable / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMetastatic Cancers1
1, 2TerminatedTreatmentMetastatic Colorectal Cancers2
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentNeuroblastomas1
1, 2TerminatedTreatmentStage IV Colorectal Cancer1
1, 2TerminatedTreatmentUnresectable Metastatic Colo-rectal Cancer1
1, 2Unknown StatusTreatmentAdvanced Non-Small Cell Lung Cancer1
1, 2WithdrawnTreatmentAdenocarcinoma of the Pancreas / Colon Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Rectal Adenocarcinoma / Stage III Pancreatic Cancer / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
1, 2WithdrawnTreatmentColorectal Cancers1
1, 2WithdrawnTreatmentGlioblastoma Multiforme (GBM)1
1, 2WithdrawnTreatmentMalignant Neoplasm of Pancreas1
1, 2WithdrawnTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingBasic ScienceMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentBiliary Tract Neoplasms1
2Active Not RecruitingTreatmentCancer - Metastatic Colorectal / Malignancies1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCarcinoma, Colorectal / Metastatic Colorectal Cancers / Neoplasms Metastasis / Neoplasms, Colorectal1
2Active Not RecruitingTreatmentColon Adenocarcinoma / ERBB2 Gene Amplification / Rectal Adenocarcinoma / Recurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage III Colon Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Rectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
2Active Not RecruitingTreatmentColorectal Adenocarcinoma / KRAS wt Allele / Metastatic Colorectal Cancers / NRAS wt Allele / RAS Wild Type / Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
2Active Not RecruitingTreatmentColorectal Cancer Liver Metastases1
2Active Not RecruitingTreatmentColorectal Cancers6
2Active Not RecruitingTreatmentColorectal Cancers / Metastatic Cancers1
2Active Not RecruitingTreatmentEfficacy and Safety1
2Active Not RecruitingTreatmentEsophageal Cancers2
2Active Not RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentEwing's Sarcoma (ES)1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Unresectable1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentMetastatic Colon Cancer / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Rectal Cancer1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers6
2Active Not RecruitingTreatmentNeoplasms, Colorectal1
2Active Not RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2Active Not RecruitingTreatmentNeuroblastomas2
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v71
2Active Not RecruitingTreatmentPancreatic Metastatic Cancer / Therapeutic Agent Toxicity1
2Active Not RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
2Active Not RecruitingTreatmentRectal Cancer Stage III1
2Active Not RecruitingTreatmentRectal Carcinoma1
2Active Not RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
2Active Not RecruitingTreatmentRecurrent Small Intestine Cancer / Small Intestine Adenocarcinoma1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentMCRC1
2CompletedNot AvailableMalignant Gliomas1
2CompletedDiagnosticUpper Gastrointestinal Tumours1
2CompletedScreeningColorectal Cancers1
2CompletedSupportive CareColorectal Cancers1
2CompletedSupportive CareColorectal Cancers / Nausea and vomiting1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Squamous Cell Carcinoma of Esophagus1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Pancreas2
2CompletedTreatmentAdenocarcinoma of the Stomach / Advanced Gastric Cancer / Malignant Neoplasm of Stomach Stage II / Stage III Gastric Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer3
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer1
2CompletedTreatmentAdult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Neoplasm / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAdvanced Colorectal Cancer1
2CompletedTreatmentAdvanced Gastric Cancer / Gastro-esophageal Junction Cancer1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAstrocytomas / Glioblastomas1
2CompletedTreatmentBiliary Cancer / Cholangiocarcinomas1
2CompletedTreatmentBiliary Tract Cancer1
2CompletedTreatmentBiliary Tract Neoplasms1
2CompletedTreatmentBladder Cancers1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors7
2CompletedTreatmentBreast Cancer Metastatic1
2CompletedTreatmentCancer of Esophagus / Cancer of the Esophagus / Esophageal Cancers / Esophagus Cancer / Neoplasms, Esophageal1
2CompletedTreatmentCancer of Stomach / Esophageal Cancers / Esophagus Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Breast6
2CompletedTreatmentCancer, Breast / Metastatic Cancers1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Neoplastic Syndrome1
2CompletedTreatmentCarcinoma of Unknown Primary1
2CompletedTreatmentCarcinoma of Unknown Primary / Colorectal Cancers / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCarcinoma of Unknown Primary / Neuroendocrine Carcinoma of the Skin / Neuroendocrine Carcinomas1
2CompletedTreatmentCarcinoma, Colorectal1
2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors1
2CompletedTreatmentChildhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood Infratentorial Ependymoma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentChildhood Cerebral Anaplastic Astrocytoma / Childhood Oligodendroglioma / Childhood Spinal Cord Neoplasm / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentColorectal Cancer (CRC)1
2CompletedTreatmentColorectal Cancers43
2CompletedTreatmentColorectal Cancers / Hepatic Metastases1
2CompletedTreatmentColorectal Cancers / Malignancies / Malignant Neoplasm of Colon / Metastatic Cancers / Metastatic Colorectal Cancers / Rectal Carcinoma1
2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Skin Rash / Skin Toxicities1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers4
2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal2
2CompletedTreatmentColorectal, Cancer1
2CompletedTreatmentEsophageal Cancers6
2CompletedTreatmentEsophageal Cancers / GE Junction Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach11
2CompletedTreatmentEstrogen Receptor Negative (ER-Negative) Breast Cancer / Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer / Metastatic Brain Tumors / Progesterone Receptor Negative (PR-Negative) Breast Cancer1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer2
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Extensive-stage Small Cell Lung Cancer (SCLC) / Metastatic Breast Cancer (MBC) / Non-small Cell Lung Cancer (NSCLC), Recurrent / Non-Small Cell Lung Cancer Recurrent / Recurrent Small Cell Lung Cancer (SCLC) / Refractory Small cell lung cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-small Cell Lung Cancer (NSCLC) / Tumors Metastatic to Brain1
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentFirst Line Metastatic Colorectal Cancer1
2CompletedTreatmentGallbladder Cancer1
2CompletedTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma1
2CompletedTreatmentGastric Adenocarcinoma / Neoplasms, Gastrointestinal1
2CompletedTreatmentGastrointestinal Cancers / Neuroendocrine Carcinomas1
2CompletedTreatmentGlioblastoma Multiforme (GBM)2
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Gliomas1
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Gliosarcoma1
2CompletedTreatmentGlioblastomas2
2CompletedTreatmentGlioblastomas / Gliosarcoma / Neoplasms, Brain1
2CompletedTreatmentGliomas / Medulloblastomas1
2CompletedTreatmentGliomas / Neoplasms, Brain1
2CompletedTreatmentHead and Neck Carcinoma2
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)5
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2CompletedTreatmentLung Cancers16
2CompletedTreatmentLung Cancers / Small Cell Lung Carcinoma1
2CompletedTreatmentMalignancies / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMalignant Gliomas1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMalignant Neoplasm of Colon / Rectum Cancer1
2CompletedTreatmentMalignant Neoplasm of Pancreas7
2CompletedTreatmentMalignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
2CompletedTreatmentMalignant Neoplasm of Stomach8
2CompletedTreatmentMalignant Neoplasm of Stomach / Neoplasms, Esophageal1
2CompletedTreatmentMalignant Neoplasm of Stomach / Peritoneal Carcinomatosis1
2CompletedTreatmentMetastatic Colorectal Cancer Patients With KRAS Mutated Tumors1
2CompletedTreatmentMetastatic Colorectal Cancers18
2CompletedTreatmentMetastatic Colorectal Cancers / Recurrent Colorectal Cancer1
2CompletedTreatmentMetastatic Non Small Cell Lung Cancer / Recurrent Non Small Cell Lung Cancer1
2CompletedTreatmentNaive Unresectable Glioblastoma1
2CompletedTreatmentNeoplasms1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Colorectal5
2CompletedTreatmentNeoplasms, Esophageal1
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Pancreatic1
2CompletedTreatmentNeuroblastomas2
2CompletedTreatmentOesophageal Carcinoma1
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPediatric High Risk Gliomas1
2CompletedTreatmentPenile Cancer1
2CompletedTreatmentProgression Free Survival of the Treatment1
2CompletedTreatmentRectal Carcinoma3
2CompletedTreatmentRectal Neoplasms1
2CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2CompletedTreatmentRecurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentRhabdomyosarcomas1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSmall Cell Lung Carcinoma1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentTumors, Solid1
2CompletedTreatmentUnresectable or Metastatic Colorectal Cancer1
2CompletedTreatmentUterine Cervical Neoplasms1
2Enrolling by InvitationTreatmentLocally Advanced or Metastatic Pancreatic Cancer1
2Enrolling by InvitationTreatmentMalignant Neoplasm of Pancreas1
2Enrolling by InvitationTreatmentRectal Carcinoma1
2Not Yet RecruitingTreatmentAdvanced Bile Duct Carcinoma / Advanced Gallbladder Carcinoma / Refractory Bile Duct Carcinoma / Refractory Gallbladder Carcinoma / Stage III Distal Bile Duct Cancer AJCC v8 / Stage III Gallbladder Cancer AJCC v8 / Stage III Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIA Distal Bile Duct Cancer AJCC v8 / Stage IIIA Gallbladder Cancer AJCC v8 / Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIB Distal Bile Duct Cancer AJCC v8 / Stage IIIB Gallbladder Cancer AJCC v8 / Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8 / Stage IV Distal Bile Duct Cancer AJCC v8 / Stage IV Gallbladder Cancer AJCC v8 / Stage IV Intrahepatic Bile Duct Cancer AJCC v8 / Stage IVA Gallbladder Cancer AJCC v8 / Stage IVB Gallbladder Cancer AJCC v81
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
2Not Yet RecruitingTreatmentBiliary Tract Cancer2
2Not Yet RecruitingTreatmentCholangiocarcinomas1
2Not Yet RecruitingTreatmentClinical Stage III Gastric Cancer AJCC v8 / Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IV Gastric Cancer AJCC v8 / Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IVA Gastric Cancer AJCC v8 / Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IVB Gastric Cancer AJCC v8 / Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Metastatic Gastric Adenocarcinoma / Metastatic Gastroesophageal Junction Adenocarcinoma / Pathologic Stage III Gastric Cancer AJCC v8 / Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIA Gastric Cancer AJCC v8 / Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIB Gastric Cancer AJCC v8 / Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIC Gastric Cancer AJCC v8 / Pathologic Stage IV Gastric Cancer AJCC v8 / Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8 / Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8 / Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 / Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 / TP53 Gene Mutation / Unresectable Gastroesophageal Junction Adenocarcinoma1
2Not Yet RecruitingTreatmentColorectal Cancers2
2Not Yet RecruitingTreatmentEsophageal Cancers1
2Not Yet RecruitingTreatmentGastrointestinal Neuroendocrine Tumor1
2Not Yet RecruitingTreatmentHead & Neck Cancer1
2Not Yet RecruitingTreatmentLocally Advanced Pancreatic Carcinoma(LAPC)1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Pancreas1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers3
2Not Yet RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2Not Yet RecruitingTreatmentPancreatic Ductal Adenocarcinoma1
2Not Yet RecruitingTreatmentRecurrent Colorectal Carcinoma / Thrombocytopenias1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2Not Yet RecruitingTreatmentTreatment Related Cancer1
2RecruitingPreventionLocally Advanced Rectal Cancer1
2RecruitingTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage I Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas2
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Cancer of Pancreas / Neoplasms, Pancreatic / Pancreatic Cancer Non-resectable / Pancreatic Cancer Resectable / Pancreatic Cancer, Adult / Pancreatic Ductal Adenocarcinoma (PDAC)1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Cancer of Pancreas / Resectable Pancreatic Cancers1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinomas / Neoplasms, Colorectal1
2RecruitingTreatmentAdvanced Biliary Tract Cancer1
2RecruitingTreatmentAdvanced Colorectal Cancer1
2RecruitingTreatmentAdvanced Esophageal Carcinoma1
2RecruitingTreatmentAdvanced Pancreatic Cancer1
2RecruitingTreatmentBiliary Cancer1
2RecruitingTreatmentBreast Cancer Metastatic1
2RecruitingTreatmentCancer of Pancreas / Chemotherapy Effect / SBRT / Unresectable Pancreatic Cancer1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
2RecruitingTreatmentCarcinoma, Colorectal / Colorectal Adenocarcinoma / Colorectal Cancer With Hepatic Metastases / Colorectal Cancers / Hepatic Metastases1
2RecruitingTreatmentCarcinoma, Small Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neuroendocrine Tumors / Ovarian Epithelial Cancer / Small Cell Lung Carcinoma1
2RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Metastatic Colorectal Cancers1
2RecruitingTreatmentCholangiocarcinomas1
2RecruitingTreatmentCholangiocarcinomas / Colorectal Cancers1
2RecruitingTreatmentColo-rectal Cancer / Hepatic Metastases2
2RecruitingTreatmentColorectal Cancers4
2RecruitingTreatmentColorectal Neoplasms, Malignant1
2RecruitingTreatmentDrug Therapy / Radiations / Rectal Neoplasms1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentGanglioneuroblastoma / Recurrent Neuroblastoma / Refractory Neuroblastoma1
2RecruitingTreatmentGastric Adenocarcinoma / Gastro-esophageal Junction Adenocarcinoma1
2RecruitingTreatmentHigh Grade Malignant Neuroendocrine Carcinoma (Diagnosis)1
2RecruitingTreatmentIncurable Colorectal Cancer / RAS-wild-type1
2RecruitingTreatmentLocally Advanced Digestive System Neuroendocrine Carcinoma / Locally Advanced Pancreatic Neuroendocrine Carcinoma / Metastatic Digestive System Neuroendocrine Carcinoma / Metastatic Pancreatic Neuroendocrine Carcinoma / Refractory Digestive System Neuroendocrine Carcinoma / Refractory Pancreatic Neuroendocrine Carcinoma / Unresectable Digestive System Neuroendocrine Carcinoma / Unresectable Pancreatic Neuroendocrine Carcinoma1
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2RecruitingTreatmentMalignant Neoplasm of Colon1
2RecruitingTreatmentMalignant Neoplasm of Pancreas2
2RecruitingTreatmentMetastatic Biliary Tract Cancer2
2RecruitingTreatmentMetastatic Colorectal Cancers13
2RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
2RecruitingTreatmentNeoadjuvant Chemotherapy / Pancreatic Adenocarcinoma Resectable1
2RecruitingTreatmentNeuroblastomas2
2RecruitingTreatmentNeuroendocrine Carcinomas2
2RecruitingTreatmentNeuroendocrine Carcinomas / Oncology1
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentOverall Survival1
2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2RecruitingTreatmentPancreatic Cancer Metastatic4
2RecruitingTreatmentPancreatic Cancer Non-resectable1
2RecruitingTreatmentPancreatic Ductal Carcinoma1
2RecruitingTreatmentPinealoblastoma1
2RecruitingTreatmentRectal Carcinoma1
2RecruitingTreatmentRecurrent Neuroblastoma1
2RecruitingTreatmentResectable Gastric and Gastroesophageal Junction Adenocarcinoma1
2RecruitingTreatmentResectable Pancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentSmall Cell Lung Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus3
2RecruitingTreatmentStage IIIB, IV, Recurrent, and Metastatic Breast Cancer1
2RecruitingTreatmentStomach Neoplasms2
2SuspendedTreatmentMalignant Neoplasm of Stomach1
2TerminatedNot AvailableColorectal Cancers1
2TerminatedDiagnosticAstrocytomas / Gliomas / Oligodendrogliomas1
2TerminatedOtherPancreatic Adenocarcinoma Metastatic1
2TerminatedTreatmentAdenocarcinoma of Ampulla / Ductal Adenocarcinoma of Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Metastatic Colon Cancer / Mucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Rectal Cancer1
2TerminatedTreatmentAdenocarcinoma of the Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Poorly Differentiated Malignant Neoplasm / Resectable Pancreatic Cancers / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer / Undifferentiated Pancreatic Carcinoma1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2TerminatedTreatmentAdenocarcinomas / Malignant Neoplasm of Colon1
2TerminatedTreatmentAppendix Tumors / Colon Tumors / Endocrine Tumors / Peritoneum Tumors / Rectum Tumors1
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBorderline Resectable Pancreatic Cancer1
2TerminatedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCervical Cancers1
2TerminatedTreatmentColorectal Adenocarcinoma / Colorectal Cancers1
2TerminatedTreatmentColorectal Cancers14
2TerminatedTreatmentDrug Therapy, Combination / Neoplasms, Colorectal / Secondary1
2TerminatedTreatmentEsophageal Cancers2
2TerminatedTreatmentEsophageal Cancers / Gastric Adenocarcinoma / Malignant Neoplasm of Stomach1
2TerminatedTreatmentEsophageal Cancers / Gastrooesophageal Cancer1
2TerminatedTreatmentGlioblastoma Multiforme (GBM)1
2TerminatedTreatmentGlioblastoma Multiforme (GBM) / Gliosarcoma / Malignant Gliomas1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentHepatic Metastases / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentHigh-Grade Gliomas1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentLung Neoplasms, Non-Small Cell Lung Cancer1
2TerminatedTreatmentMalignant Glioma of Brain1
2TerminatedTreatmentMalignant Neoplasm of Colon1
2TerminatedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
2TerminatedTreatmentMalignant Neoplasm of Pancreas2
2TerminatedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
2TerminatedTreatmentMetastases / Neoplasms, Colorectal1
2TerminatedTreatmentMetastatic Colorectal Cancers6
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2TerminatedTreatmentNeoplasms, Colorectal3
2TerminatedTreatmentNeoplasms, Colorectal / Neoplasms, Hepatic1
2TerminatedTreatmentNeoplasms, Colorectal / Severe or persistent diarrhea1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentOesophageal Carcinoma1
2TerminatedTreatmentRectal Carcinoma1
2TerminatedTreatmentRecurrent Colorectal Carcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRenal Cancers1
2TerminatedTreatmentSarcomas1
2Unknown StatusDiagnosticRecurrent Malignant Gliomas1
2Unknown StatusTreatmentAdvanced Esophageal Squamous Carcinoma1
2Unknown StatusTreatmentBiliary Tract Cancer1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Recurrent Glioblastoma Multiforme1
2Unknown StatusTreatmentCarcinoma, Colorectal1
2Unknown StatusTreatmentColonic Neoplasms1
2Unknown StatusTreatmentColorecal Neoplasms / Secondary1
2Unknown StatusTreatmentColorectal Cancers9
2Unknown StatusTreatmentColorectal Cancers / Metastatic Cancers2
2Unknown StatusTreatmentEsophageal Cancers1
2Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentHepatic Lesions / Hepatic Metastases / Metastatic Colorectal Cancers1
2Unknown StatusTreatmentLiver Cancer1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2Unknown StatusTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentLung Cancers2
2Unknown StatusTreatmentMalignant Neoplasm of Stomach2
2Unknown StatusTreatmentMetastatic Colorectal Cancers2
2Unknown StatusTreatmentMetastatic / Second-Line / Stomach Neoplasms1
2Unknown StatusTreatmentNeoadjuvant Therapy / Rectal Neoplasms1
2Unknown StatusTreatmentNeoadjuvant Treatment / Rectal Neoplasms1
2Unknown StatusTreatmentNeoplasms, Brain1
2Unknown StatusTreatmentNeoplasms, Colorectal1
2Unknown StatusTreatmentSarcomas2
2Unknown StatusTreatmentSmall Cell Carcinoma of Lung1
2Unknown StatusTreatmentStage IV Gastric Cancer With Metastasis1
2Unknown StatusTreatmentStomach Neoplasms1
2WithdrawnTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum1
2WithdrawnTreatmentBiliary Tract Cancer1
2WithdrawnTreatmentColorectal Adenocarcinoma Metastatic to the Liver1
2WithdrawnTreatmentColorectal Cancers2
2WithdrawnTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
2WithdrawnTreatmentColorectal Cancers / Metastatic Cancers1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMalignant Gliomas1
2WithdrawnTreatmentMalignant Neoplasm of Stomach1
2WithdrawnTreatmentMetastatic Colorectal Cancers2
2WithdrawnTreatmentPediatric Solid Tumors1
2, 3Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2, 3Active Not RecruitingTreatmentResectable Prancreas Carcinoma1
2, 3CompletedDiagnosticColorectal Cancers1
2, 3CompletedTreatmentColorectal Cancers2
2, 3CompletedTreatmentEsophageal Cancers1
2, 3CompletedTreatmentMalignant Neoplasm of Pancreas1
2, 3CompletedTreatmentMalignant Neoplasm of Stomach1
2, 3CompletedTreatmentMetastatic Colorectal Cancers2
2, 3Not Yet RecruitingTreatmentMalignant Tumor of Pancreas Metastatic to Liver1
2, 3RecruitingTreatmentChildhood Hepatocellular Carcinoma / Childhood Malignant Liver Neoplasm / Elevated Alpha-Fetoprotein / Hepatoblastomas / Hepatocellular Malignant Neoplasm, Not Otherwise Specified / SMARCB1 Gene Mutation1
2, 3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2, 3RecruitingTreatmentMalignant Neoplasm of Pancreas1
2, 3Unknown StatusTreatmentGlioblastomas1
2, 3Unknown StatusTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2, 3Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
3Active Not RecruitingTreatmentAdult Malignant Mesenchymoma / Adult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Botryoid-Type Embryonal Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Childhood Malignant Mesenchymoma / Non-Metastatic Childhood Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
3Active Not RecruitingTreatmentAlpha Fetoprotein Increased / PRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3Active Not RecruitingTreatmentBRAF V600E-mutant Metastatic Colorectal Cancer1
3Active Not RecruitingTreatmentColorectal Cancers2
3Active Not RecruitingTreatmentEsophagogastric Junction Carcinoma / Oesophageal Carcinoma2
3Active Not RecruitingTreatmentGastric Cancer Third Line / Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma1
3Active Not RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
3Active Not RecruitingTreatmentOesophageal Carcinoma1
3CompletedNot AvailableNeoplasms Metastasis / Stomach Neoplasms1
3CompletedOtherRectal Adenocarcinoma1
3CompletedTreatmentAdenocarcinoma of the Colon / Stage III Colon Cancer2
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdvanced Colorectal Cancer1
3CompletedTreatmentColorectal Cancers14
3CompletedTreatmentColorectal Cancers / Metastasis1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers2
3CompletedTreatmentCancer treatment / Colorectal Cancers / Metastatic Cancers1
3CompletedTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
3CompletedTreatmentEpidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer1
3CompletedTreatmentInoperable Gastric Cancer1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
3CompletedTreatmentLung Cancers2
3CompletedTreatmentMalignant Neoplasm of Stomach2
3CompletedTreatmentMetastatic Colorectal Cancers5
3CompletedTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IIIA Colon Cancer / Stage IIIA Rectal Cancer / Stage IIIB Colon Cancer / Stage IIIB Rectal Cancer / Stage IIIC Colon Cancer / Stage IIIC Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3CompletedTreatmentMucinous Adenocarcinoma of the Rectum / Rectal Mucinous Adenocarcinoma / Rectal Signet Ring Cell Adenocarcinoma / Recurrent Rectal Cancer / Recurrent Rectal Carcinoma / Signet Ring Adenocarcinoma of the Rectum / Stage IIA Rectal Cancer / Stage IIA Rectal Cancer AJCC v7 / Stage IIB Rectal Cancer / Stage IIB Rectal Cancer AJCC v7 / Stage IIC Rectal Cancer / Stage IIC Rectal Cancer AJCC v7 / Stage IIIA Rectal Cancer / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Rectal Cancer / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Rectal Cancer / Stage IIIC Rectal Cancer AJCC v7 / Stage IVA Rectal Cancer / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Rectal Cancer / Stage IVB Rectal Cancer AJCC v71
3CompletedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
3CompletedTreatmentNeoplasms, Colorectal1
3CompletedTreatmentNeoplasms, Colorectal / Neoplasms, Hepatic1
3CompletedTreatmentPancreatic Cancer Metastatic1
3CompletedTreatmentSarcomas1
3CompletedTreatmentSmall Cell Lung Carcinoma1
3CompletedTreatmentTumors, Solid1
3CompletedTreatmentUnknown Primary Neoplasms1
3Not Yet RecruitingTreatmentAdenocarcinoma of the Pancreas1
3Not Yet RecruitingTreatmentCarcinoma, Colorectal1
3Not Yet RecruitingTreatmentColorectal Adenocarcinoma1
3Not Yet RecruitingTreatmentColorectal Cancers1
3Not Yet RecruitingTreatmentHepatic Metastases / Metastatic Colorectal Cancers1
3Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3Not Yet RecruitingTreatmentMetastatic Adenocarcinoma of the Pancreas1
3Not Yet RecruitingTreatmentMetastatic Colorectal Cancers / Stage III Colorectal Cancer1
3RecruitingTreatmentBotryoid-Type Embryonal Rhabdomyosarcoma / Rhabdomyosarcoma, Alveolar / Rhabdomyosarcoma, Embryonal / Rhabdomyosarcomas / Sclerosing Rhabdomyosarcoma / Spindle Cell Rhabdomyosarcoma / Untreated Childhood Rhabdomyosarcoma1
3RecruitingTreatmentCarcinoma NOS / Malignant Neoplasm of Pancreas1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentColon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) / Colon Cancer (High-risk Stage III; pT4N1 or pT1 to 4 N2)1
3RecruitingTreatmentColorectal Cancers / Hepatic Metastases1
3RecruitingTreatmentDigestive System Neoplasms / Intestinal Neoplasms / Neoplasms Metastasis / Neoplasms, Colorectal / Neoplasms, Gastrointestinal1
3RecruitingTreatmentEffects of Chemotherapy / General Surgery / Local Neoplasm Recurrences / Metastasis / Neoplasms, Colorectal1
3RecruitingTreatmentEsophageal Squamous Cell Carcinoma (ESCC)1
3RecruitingTreatmentEwing Family of Tumors / Ewing's Sarcoma (ES) / Ewing's Tumor Metastatic / Ewing's Tumor Recurrent / Metastatic Ewing's Sarcoma / Neoplasms / Neoplasms by Histologic Type / Neoplasms, Bone Tissue / Neoplasms, Connective and Soft Tissue / Neoplasms, Connective Tissue / Rare Diseases / Sarcomas1
3RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3RecruitingTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Cancer Metastatic1
3RecruitingTreatmentLocally Advanced Rectal Cancer1
3RecruitingTreatmentMalignant Neoplasm of Pancreas1
3RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
3RecruitingTreatmentMetastatic Colorectal Cancers6
3RecruitingTreatmentNeoplasms, Esophageal1
3RecruitingTreatmentPancreatic Cancer Metastatic1
3RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
3SuspendedTreatmentMetastatic Colorectal Cancers1
3TerminatedSupportive CareColorectal Cancers / Severe or persistent diarrhea1
3TerminatedTreatmentBrain Cancer / Choroid Plexus Tumors1
3TerminatedTreatmentColorectal Cancers2
3TerminatedTreatmentLocally Advanced Malignant Neoplasm / Malignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
3TerminatedTreatmentMetastatic Colorectal Cancers1
3TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
3Unknown StatusTreatmentColorectal Cancers7
3Unknown StatusTreatmentColorectal Cancers / Neoplasms Metastasis1
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
3Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
3Unknown StatusTreatmentMetastatic Colorectal Cancers2
4Active Not RecruitingTreatmentMalignant Neoplasm of Stomach / Stage IV Colorectal Cancer1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
4CompletedTreatmentMetastatic Colorectal Cancers1
4CompletedTreatmentTumors, Solid1
4CompletedTreatmentUpper Gastrointestinal Tumours1
4RecruitingTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma / Stage IIB Gastric Cancer / Stage IIIA Esophageal Adenocarcinoma / Stage IIIA Gastric Cancer / Stage IIIB Esophageal Adenocarcinoma / Stage IIIB Gastric Cancer / Stage IIIC Esophageal Adenocarcinoma / Stage IIIC Gastric Cancer1
4RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
4RecruitingTreatmentMalignant Neoplasm of Stomach1
4WithdrawnTreatmentMetastatic Hepatic Cancer / Neoplasms, Hepatic / Secondary Liver Cancer1
Not AvailableActive Not RecruitingNot AvailableRecurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma / Recurrent Rhabdomyosarcoma1
Not AvailableActive Not RecruitingTreatmentLocalized Pancreas Cancer / Malignant Neoplasm of Pancreas / Non-metastatic Pancreas Cancer1
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableCompletedNot AvailableBiomarkers / Chemotherapy Effect / Metastatic Colorectal Cancers1
Not AvailableCompletedNot AvailableCancer of the Ovary / Cervical Cancers / Gastric Cancer (Inoperable and Recurrent) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableCompletedNot AvailableColorectal Cancers1
Not AvailableCompletedNot AvailableMetastatic Colorectal Cancers2
Not AvailableCompletedTreatmentMetastatic Colorectal Cancers1
Not AvailableCompletedTreatmentRectal Carcinoma1
Not AvailableNot Yet RecruitingNot AvailableMetastatic Colorectal Cancers1
Not AvailableNot Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
Not AvailableRecruitingNot AvailableBiliary Tract Cancer / Colo-rectal Cancer / Esophageal Cancers / Gall Bladder Cancer / Liver Cancer / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
Not AvailableRecruitingNot AvailableColorectal Adenocarcinoma / Hepatic Metastases1
Not AvailableRecruitingNot AvailablePancreatic Cancer Metastatic1
Not AvailableRecruitingTreatmentMetastatic Colorectal Cancers1
Not AvailableTerminatedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
Not AvailableUnknown StatusNot AvailableMetastatic Colorectal Cancers1
Not AvailableUnknown StatusBasic ScienceNeoplasms, Colorectal / Secondary1
Not AvailableWithdrawnTreatmentCentral Nervous System Metastases / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
Not AvailableWithdrawnTreatmentColorectal Cancers1
Not AvailableWithdrawnTreatmentColorectal Cancers / Hepatic Metastases1
Not AvailableWithdrawnTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1

Pharmacoeconomics

Manufacturers
  • Pfizer inc
  • Accord healthcare inc
  • Actavis totowa llc
  • Akorn inc
  • App pharmaceuticals
  • Bedford laboratories
  • Dr reddys laboratories ltd
  • Ebewe pharma ges mbh nfg kg
  • Fresenius kabi oncology plc
  • Hospira inc
  • Pharmaforce inc
  • Pliva lachema as
  • Sandoz inc
  • Sun pharma global inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
Packagers
  • Actavis Group
  • APP Pharmaceuticals
  • Barr Pharmaceuticals
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cipla Ltd.
  • Ebewe Pharma
  • Fresenius Kabi AB
  • Greenstone LLC
  • Hospira Inc.
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Pfizer Inc.
  • Pharmacia Inc.
  • Pliva Inc.
  • Sagent Pharmaceuticals
  • Sandoz
  • SC Sindan Pharma SRL
  • Sicor Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
SolutionIntravenous20 mg
SolutionIntravenous
InjectionIntravenous100 mg/5mL
InjectionIntravenous20 mg/1mL
InjectionIntravenous40 mg/2mL
InjectionIntravenous500 mg/25mL
Injection, solutionIntravenous100 mg/5mL
Injection, solutionIntravenous20 mg/1mL
Injection, solutionIntravenous40 mg/2mL
InjectionIntravenous4.3 mg/1mL
Injection, powder, for solutionIntravenous4.3 mg/1mL
SuspensionIntravenous43 mg
Prices
Unit descriptionCostUnit
Irinotecan hcl 40 mg/2 ml inj138.07USD ml
Camptosar 20 mg/ml vial36.0USD ml
Irinotecan hcl 40 mg/2 ml vial22.2USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2202531No2005-05-032015-10-11Canada
CA2294031No2005-01-182018-07-27Canada
US6403569Yes2002-06-112020-10-28Us
US6794370Yes2004-09-212020-11-01Us
US8703181No2014-04-222025-05-02Us
US8329213No2012-12-112025-05-02Us
US8992970No2015-03-312025-05-02Us
US8147867No2012-04-032028-08-29Us
US9364473No2016-06-142033-06-12Us
US9492442No2016-11-152033-06-12Us
US9339497No2016-05-172033-06-12Us
US9452162No2016-09-272033-06-12Us
US9717724No2017-08-012033-06-12Us
US9730891No2017-08-152025-05-02Us
US9724303No2017-08-082025-05-02Us
US9782349No2017-10-102025-05-02Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)222-223 °CNot Available
water solubilitySolubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.107 mg/mLALOGPS
logP3.94ALOGPS
logP2.78ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)11.71ChemAxon
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area112.51 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity161.33 m3·mol-1ChemAxon
Polarizability65.27 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.969
Blood Brain Barrier+0.6284
Caco-2 permeable-0.6065
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor IInhibitor0.7092
P-glycoprotein inhibitor IINon-inhibitor0.5337
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8174
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.8564
CYP450 2C9 inhibitorNon-inhibitor0.7377
CYP450 2D6 inhibitorNon-inhibitor0.7779
CYP450 2C19 inhibitorNon-inhibitor0.6625
CYP450 3A4 inhibitorInhibitor0.8295
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5081
Ames testNon AMES toxic0.6977
CarcinogenicityNon-carcinogens0.8045
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.7960 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9457
hERG inhibition (predictor II)Inhibitor0.5413
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0091000000-b15811b1af58e71b3ec6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0101190000-eed1a0e57a719811aa8e

Taxonomy

Description
This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Camptothecins
Sub Class
Not Available
Direct Parent
Camptothecins
Alternative Parents
Quinolines and derivatives / Pyranopyridines / Piperidinecarboxylic acids / Aminopiperidines / Pyridinones / Benzenoids / Tertiary alcohols / Carbamate esters / Heteroaromatic compounds / Trialkylamines
show 11 more
Substituents
Camptothecin / Pyranopyridine / Quinoline / Piperidinecarboxylic acid / 4-aminopiperidine / Pyridinone / Piperidine / Pyridine / Benzenoid / Carbamic acid ester
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyranoindolizinoquinoline (CHEBI:80630) / Quinoline alkaloids (C16641)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a singl...
Gene Name
TOP1
Uniprot ID
P11387
Uniprot Name
DNA topoisomerase 1
Molecular Weight
90725.19 Da
References
  1. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S: Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004 Jul 20;110(6):921-7. [PubMed:15170677]
  2. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol. 2004 Apr;4(1):25-35. [PubMed:15255290]
  3. Yang X, Hu Z, Chan SY, Chan E, Goh BC, Duan W, Zhou S: Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem. 2005;12(11):1343-58. [PubMed:15975002]
  4. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T: Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006 Mar 8;234(1):81-9. Epub 2005 Nov 23. [PubMed:16309825]
  5. Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S: Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006;12(3):313-25. [PubMed:16454746]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  8. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Releases the supercoiling and torsional tension of DNA introduced during duplication of mitochondrial DNA by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-str...
Gene Name
TOP1MT
Uniprot ID
Q969P6
Uniprot Name
DNA topoisomerase I, mitochondrial
Molecular Weight
69871.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S: Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004 Jul 20;110(6):921-7. [PubMed:15170677]
  4. Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol. 2004 Apr;4(1):25-35. [PubMed:15255290]
  5. Yang X, Hu Z, Chan SY, Chan E, Goh BC, Duan W, Zhou S: Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem. 2005;12(11):1343-58. [PubMed:15975002]
  6. Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T: Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006 Mar 8;234(1):81-9. Epub 2005 Nov 23. [PubMed:16309825]
  7. Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S: Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006;12(3):313-25. [PubMed:16454746]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  9. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  10. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  2. Kuhn JG: Pharmacology of irinotecan. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42. [PubMed:9726089]
  3. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 2000 May;6(5):2012-20. [PubMed:10815927]
  4. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res. 2000 May;6(5):2012-20. [PubMed:10815927]
  2. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Potential CYP2B6 Substrates, Inhibitors, Inudcers (https://ctep.cancer.gov/protocoldevelopment/docs/cyp2b6.doc) [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Flockhart Table of Drug Interactions [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Kuhn JG: Pharmacology of irinotecan. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42. [PubMed:9726089]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. [PubMed:9342501]
  2. Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345. [PubMed:19852077]
  3. Kuhn JG: Pharmacology of irinotecan. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42. [PubMed:9726089]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Methylumbelliferyl-acetate deacetylase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and ...
Gene Name
CES2
Uniprot ID
O00748
Uniprot Name
Cocaine esterase
Molecular Weight
61806.41 Da
References
  1. Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF: Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11. [PubMed:15100172]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Link [Link]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, Burckhardt G, Hagos Y: Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009 Feb 15;69(4):1494-501. doi: 10.1158/0008-5472.CAN-08-2483. Epub 2009 Feb 3. [PubMed:19190342]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005 Mar;33(3):434-9. Epub 2004 Dec 17. [PubMed:15608127]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, Akiyama SI: ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8. [PubMed:10220571]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. [PubMed:12488537]
  2. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH: Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res. 2001 Apr;7(4):935-41. [PubMed:11309344]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Kroetz DL: Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006 Sep 10;24(26):4225-7. Epub 2006 Aug 8. [PubMed:16895999]
  2. Han JY, Lim HS, Park YH, Lee SY, Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20. doi: 10.1016/j.lungcan.2007.12.003. Epub 2008 Jan 24. [PubMed:18221820]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Kroetz DL: Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006 Sep 10;24(26):4225-7. Epub 2006 Aug 8. [PubMed:16895999]
  2. Han JY, Lim HS, Park YH, Lee SY, Lee JS: Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20. doi: 10.1016/j.lungcan.2007.12.003. Epub 2008 Jan 24. [PubMed:18221820]

Drug created on June 13, 2005 07:24 / Updated on October 13, 2019 23:23